UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2008.
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to .
Commission File Number: 000-50884
STEREOTAXIS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 94-3120386 | |
(State of Incorporation) | (I.R.S. employer identification no.) |
4320 Forest Park Avenue Suite 100 St. Louis, Missouri |
63108 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (314) 678-6100
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ¨ Accelerated filer x Non-accelerated filer ¨ Smaller reporting company ¨
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes x No
The number of outstanding shares of the registrants common stock on April 30, 2008 was 37,191,731.
INDEX TO FORM 10-Q
Page | ||||||
Part I |
Financial Information | |||||
Item 1. | Financial Statements (unaudited) | |||||
Balance Sheets | 3 | |||||
Statements of Operations | 4 | |||||
Statements of Cash Flows | 5 | |||||
Notes to Financial Statements | 6-11 | |||||
Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations | 12-15 | ||||
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 16 | ||||
Item 4. | Controls and Procedures | 16 | ||||
Part II |
Other Information | |||||
Item 1 | Legal Proceedings | 17 | ||||
Item 1A. | Risk Factors | 17 | ||||
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 17 | ||||
Item 3. | Defaults upon Senior Securities | 17 | ||||
Item 4. | Submission of Matters to a Vote of Security Holders | 17 | ||||
Item 5. | Other Information | 17 | ||||
Item 6. | Exhibits | 17 | ||||
Signatures | 18 | |||||
Exhibit Index | 19 |
2
ITEM 1. | FINANCIAL STATEMENTS |
BALANCE SHEETS
March 31, 2008 |
December 31, 2007 |
|||||||
(unaudited) | ||||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 10,973,108 | $ | 17,022,200 | ||||
Short-term investments |
| 6,634,178 | ||||||
Accounts receivable, net of allowance of $177,719 and $189,040 in 2008 and 2007, respectively |
12,500,839 | 13,757,270 | ||||||
Current portion of long-term receivables |
214,342 | 136,430 | ||||||
Inventories |
10,537,151 | 9,964,460 | ||||||
Prepaid expenses and other current assets |
5,128,255 | 3,421,202 | ||||||
Total current assets |
39,353,695 | 50,935,740 | ||||||
Property and equipment, net |
6,607,590 | 7,011,763 | ||||||
Intangible assets, net |
1,377,778 | 1,411,111 | ||||||
Long-term receivables |
483,376 | 272,859 | ||||||
Long-term investments |
469,025 | | ||||||
Other assets |
744,321 | 844,321 | ||||||
Total assets |
$ | 49,035,785 | $ | 60,475,794 | ||||
Liabilities and stockholders equity |
||||||||
Current liabilities: |
||||||||
Current maturities of long-term debt |
$ | 5,888,889 | $ | 972,222 | ||||
Accounts payable |
7,124,879 | 7,349,426 | ||||||
Accrued liabilities |
9,044,925 | 11,913,418 | ||||||
Deferred contract revenue |
10,132,609 | 8,774,958 | ||||||
Total current liabilities |
32,191,302 | 29,010,024 | ||||||
Long-term debt, less current maturities |
833,333 | 6,000,000 | ||||||
Long-term deferred contract revenue |
1,266,579 | 942,573 | ||||||
Other liabilities |
344,194 | 328,790 | ||||||
Stockholders equity: |
||||||||
Preferred stock, par value $0.001; 10,000,000 shares authorized at 2008 and 2007, none outstanding at 2008 and 2007 |
| | ||||||
Common stock, par value of $0.001; 100,000,000 shares authorized at 2008 and 2007, 37,187,551 and 37,132,529 shares issued at 2008 and 2007, respectively |
37,188 | 37,133 | ||||||
Additional paid in capital |
280,172,707 | 276,433,662 | ||||||
Treasury stock, 40,151 shares at 2008 and 2007 |
(205,999 | ) | (205,999 | ) | ||||
Accumulated deficit |
(265,603,519 | ) | (252,072,353 | ) | ||||
Accumulated other comprehensive income |
| 1,964 | ||||||
Total stockholders equity |
14,400,377 | 24,194,407 | ||||||
Total liabilities and stockholders equity |
$ | 49,035,785 | $ | 60,475,794 | ||||
See accompanying notes.
3
STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended March 31, | ||||||||
2008 | 2007 | |||||||
Revenue: |
||||||||
Systems |
$ | 4,377,398 | $ | 7,207,443 | ||||
Disposables, service and accessories |
2,651,053 | 1,953,512 | ||||||
Total revenue |
7,028,451 | 9,160,955 | ||||||
Cost of revenue: |
||||||||
Systems |
1,856,102 | 2,529,808 | ||||||
Disposables, service and accessories |
569,960 | 720,540 | ||||||
Total cost of revenue |
2,426,062 | 3,250,348 | ||||||
Gross margin |
4,602,389 | 5,910,607 | ||||||
Operating expenses: |
||||||||
Research and development |
4,698,797 | 5,694,691 | ||||||
Sales and marketing |
7,663,713 | 6,079,922 | ||||||
General and administrative |
5,476,122 | 4,942,938 | ||||||
Total operating expenses |
17,838,632 | 16,717,551 | ||||||
Operating loss |
(13,236,243 | ) | (10,806,944 | ) | ||||
Interest income |
107,728 | 382,454 | ||||||
Interest expense |
(402,651 | ) | (79,617 | ) | ||||
Net loss |
$ | (13,531,166 | ) | $ | (10,504,107 | ) | ||
Net loss per common share: |
$ | (0.37 | ) | $ | (0.31 | ) | ||
Basic and diluted |
||||||||
Weighted average shares used in computing net loss per common share: |
36,493,662 | 34,409,573 | ||||||
Basic and diluted |
See accompanying notes.
4
STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended March 31, | ||||||||
2008 | 2007 | |||||||
Cash flows from operating activities |
||||||||
Net loss |
$ | (13,531,166 | ) | $ | (10,504,107 | ) | ||
Adjustments to reconcile net loss to cash used in operating activities: |
||||||||
Depreciation |
564,195 | 312,268 | ||||||
Amortization (accretion) |
15,231 | (64,289 | ) | |||||
Amortization of warrants |
237,129 | | ||||||
Share-based compensation |
1,353,275 | 1,245,884 | ||||||
Gain on asset disposal |
3,068 | | ||||||
Impairment charge, long-term investment |
31,598 | | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
1,256,431 | 3,430,735 | ||||||
Other receivables |
(288,736 | ) | (74,623 | ) | ||||
Inventories |
(572,691 | ) | (1,733,498 | ) | ||||
Prepaid expenses and other current assets |
(213,138 | ) | 945,347 | |||||
Other assets |
100,000 | 5,142 | ||||||
Accounts payable |
(224,547 | ) | (524,631 | ) | ||||
Accrued liabilities |
(2,868,493 | ) | 1,005,079 | |||||
Deferred contract revenue |
1,681,657 | (726,212 | ) | |||||
Other |
15,404 | 394,541 | ||||||
Net cash used in operating activities |
(12,440,783 | ) | (6,288,364 | ) | ||||
Cash flows from investing activities |
||||||||
Purchase of equipment |
(163,090 | ) | (1,577,488 | ) | ||||
Proceeds from the maturity/sale of available-for-sale investments |
6,150,000 | 19,700,000 | ||||||
Purchase of available-for-sale investments |
| (986,780 | ) | |||||
Net cash provided by investing activities |
5,986,910 | 17,135,732 | ||||||
Cash flows from financing activities |
||||||||
Payments under long-term debt |
(250,000 | ) | (249,999 | ) | ||||
Proceeds from issuance of stock, net of issuance costs |
654,781 | 20,636,518 | ||||||
Net cash provided by financing activities |
404,781 | 20,386,519 | ||||||
Net increase (decrease) in cash and cash equivalents |
(6,049,092 | ) | 31,233,887 | |||||
Cash and cash equivalents at beginning of period |
17,022,200 | 15,210,495 | ||||||
Cash and cash equivalents at end of period |
$ | 10,973,108 | $ | 46,444,382 | ||||
See accompanying notes.
5
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
Basis of Presentation
The accompanying unaudited financial statements of Stereotaxis, Inc. (the Company) have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three month period ended March 31, 2008 are not necessarily indicative of the results that may be expected for the year ended December 31, 2008 or for future operating periods. These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Companys Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 17, 2008 for the year ended December 31, 2007.
Recently Adopted Accounting Pronouncements
Effective January 1, 2008, the Company adopted SFAS No. 157, Fair Value Measurements (SFAS 157). In February 2008, the FASB issued FASB Staff Position No. FAS 157-2, Effective Date of FASB Statement No. 157, which provides a one year deferral of the effective date of SFAS 157 for non-financial assets and non-financial liabilities, except those that are recognized or disclosed in the financial statements at fair value at least annually. The Company has adopted the provisions of SFAS 157 with respect to its financial assets and liabilities only. SFAS 157 applies to those previously issued pronouncements that prescribe fair value as the relevant measure of value, except SFAS 123(R) and related interpretations and pronouncements that require or permit measurement similar to fair value but are not intended to measure fair value. The adoption of SFAS 157 did not have a material impact on the Companys financial condition results of operations or cash flows. SFAS 157 provides a single definition of fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Valuation techniques used to measure fair value under SFAS 157 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows:
Level 1 - Quoted prices in active markets for identical assets or liabilities
Level 2 - Inputs other than Level 1 inputs that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Effective January 1, 2008, the Company adopted SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (SFAS 159). SFAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. Adoption of SFAS 159 did not have an impact on the Companys financial position, results of operations, or cash flows as the Company elected not to use the fair value measurement option on its financial instruments and other applicable items.
Effective January 1, 2008, the Company adopted Emerging Issues Task force EITF Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities (EITF 07-3). EITF 07-3 requires that nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities be deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed. The adoption of EITF 07-3 did not have an impact on the Companys financial position, results of operations or cash flows.
Revenue and Costs of Revenue
For arrangements with multiple deliverables, the Company allocates the total revenue to each deliverable based on the provisions of Staff Accounting Bulletin 104 (SAB 104) Revenue Recognition and Emerging Issues Task Force (EITF) Issue No. 00-21, Revenue Arrangements with Multiple Deliverables (EITF 00-21), and recognizes revenue for each separate element as the criteria are met. In the second quarter of 2007, the Company determined that installation met the criteria under SAB 104 and EITF
6
Issue 00-21 for recognition as a separate element or unit of accounting. Revenue for system sales is recognized for the portion of sales price due upon delivery, provided that delivery has occurred, title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. The greater of the fair market value or the amount of the sales price due upon installation is recognized as revenue when the standard installation process is complete. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since such arrangements do not include an installation element or right of return privileges. If uncertainties exist regarding collectability, the Company recognizes revenue when those uncertainties are resolved. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multi-element arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. The Company recognizes revenue from disposable device sales or accessories upon shipment and an appropriate reserve for returns is established. The Company recognizes fees earned on the shipment of product to customers as revenue and recognizes costs incurred on the shipment of product to customers as cost of revenue.
Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Net Loss Per Common Share
Basic net loss per common share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the loss for the period by the weighted average number of common and common equivalent shares outstanding during the period as described below.
The Company has deducted unearned restricted shares from the calculation of shares used in computing net loss per share, basic and diluted. The Company has excluded all outstanding options, stock appreciation rights and warrants from the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The Company deducted a weighted average of 640,895 unearned restricted shares from the calculation of net loss per common share for the three months ended March 31, 2008. As of March 31, 2008, the Company had 3,749,106 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $8.09 per share and 572,246 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $7.70 per share.
Stock-Based Compensation
The Company accounts for its grants of stock options, stock appreciation rights, restricted shares and its employee stock purchase plan in accordance with the provisions of Financial Accounting Standards Board Statement No. 123(R), Share-Based Payment (SFAS 123(R)), using the modified prospective transition method. SFAS 123(R) requires the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests.
The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Companys historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.
Stock options and stock appreciation rights issued to certain non-employees, including individuals for scientific advisory services, are recorded at their fair value as determined in accordance with SFAS 123(R) and Emerging Issues Task Force (EITF) No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction With Selling, Goods or Services, and recognized over the service period. Deferred compensation for options granted to such non-employees is periodically remeasured through the vesting or forfeiture date.
7
At March 31, 2008, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Companys equity incentive plans that has not yet been recognized was approximately $10.4 million, net of estimated forfeitures of approximately $1.3 million. This cost will be amortized on a straight-line basis over the underlying estimated service periods, generally four years, and may be adjusted for subsequent changes in estimated forfeitures and anticipated vesting periods.
Stock Award Plans
The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation that are described in the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2007. At March 31, 2008, the Board of Directors has reserved a total of 4,303,758 shares of the Companys common stock to provide for current and future grants under its various equity plans.
A summary of the option and stock appreciation rights activity for the three months ended March 31, 2008 is as follows:
Number of Options/SARs |
Range of Exercise Price |
Weighted Average Exercise Price per Share | ||||||
Outstanding, December 31, 2007 |
3,324,509 | $0.25 - $14.84 | $ | 8.72 | ||||
Granted |
688,515 | $4.00 - $6.86 | $ | 6.41 | ||||
Exercised |
(40,902 | ) | $1.37 - $9.19 | $ | 7.76 | |||
Forfeited |
(223,016 | ) | $6.77 - $13.02 | $ | 12.43 | |||
Outstanding, March 31, 2008 |
3,749,106 | $0.25 - $14.84 | $ | 8.09 | ||||
A summary of the restricted share grant activity for the three months ended March 31, 2008 is as follows:
Number of Shares | Weighted Average Grant Date Fair Value per Share | |||||
Outstanding, December 31, 2007 |
721,415 | $ | 10.60 | |||
Granted |
76,700 | $ | 6.06 | |||
Vested |
(36,961 | ) | $ | 10.58 | ||
Forfeited |
(94,948 | ) | $ | 11.86 | ||
Outstanding, March 31, 2008 |
666,206 | $ | 9.90 | |||
A summary of the restricted stock outstanding as of March 31, 2008 is as follows:
Number of Shares | ||
Time based restricted shares |
198,877 | |
Performance based restricted shares |
467,329 | |
Outstanding, March 31, 2008 |
666,206 | |
Comprehensive Loss
Comprehensive income (loss) generally represents all changes in stockholders equity except those resulting from investments by stockholders, and included the Companys unrealized income (loss) on marketable securities. Comprehensive income (loss) for the three month periods ended March 31, 2008 and 2007 included unrealized gain (loss) on available-for-sale investments of ($1,964) and ($1,724) respectively. Accumulated other comprehensive income at March 31, 2008 and 2007 was $0 and $1,964 respectively.
8
Investments
Investments consist of the following available-for-sale securities at fair value:
March 31, 2008 |
December 31, 2007 | |||||
Short-term investments |
||||||
Commercial paper |
$ | | $ | 6,133,863 | ||
Auction rate securities |
| 500,315 | ||||
Long-term investments |
||||||
Auction rate securities |
469,025 | | ||||
$ | 469,025 | $ | 6,634,178 | |||
In accordance with SFAS 157, the following table represents the Companys fair value hierarchy for its financial assets (cash equivalents and investments) measured at fair value on a recurring basis as of March 31, 2008:
Level 1 | Level 2 | Level 3 | Total | |||||||||
Money market (1) |
$ | 4,555,887 | $ | | $ | | $ | 4,555,887 | ||||
Auction rate securities |
| | 469,025 | 469,025 | ||||||||
Total |
$ | 4,555,887 | $ | | $ | 469,025 | $ | 5,024,912 | ||||
(1) | Included in cash equivalents |
The following table provides a summary of changes in fair value of the Companys Level 3 financial assets as of March 31, 2008:
Balance at December 31, 2007 |
$ | 500,000 | ||
Interest receivable |
623 | |||
Impairment charge |
(31,598 | ) | ||
Balance at March 31, 2008 |
$ | 469,025 | ||
At March 31, 2008, the Company had invested $500,000 in a taxable auction rate security (ARS). The ARS held by the Company is a private placement security with a long-term stated maturity for which the interest rate is reset through a Dutch auction every 28 days. The Companys ARS was issued by South Carolina Student Loan Corporation and currently carries a AAA/Aaa rating. The ARS has not experienced any payment defaults and is insured by AMBAC. Until recently, the auctions have provided a liquid market for these securities as investors could readily sell their investments at auction.
Historically, the fair value of ARS investments has generally approximated par value due to the frequent resets through the auction process. With the liquidity issues experienced in global credit and capital markets, the Company has been unable to sell its ARS at auction during 2008, as the amount of securities submitted for sale exceeded the amount of purchase orders. Accordingly, the Company reviewed the estimated fair value of its investment in the ARS as of March 31, 2008 utilizing a discounted cash flow model using estimates for interest rates, timing and amount of cash flows and expected holding periods of the ARS. Based on this assessment of fair value, as of March 31, 2008, the Company determined there was a decline in the fair value of its ARS investments of approximately $32,000 which was deemed to be an other-than-temporary impairment charge in accordance with SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities, and recorded a realized loss in the statement of operations. As of March 31, 2008 the Company reclassified its ARS investment balance from short-term investments to non-current investments on its balance sheet.
If uncertainties in the credit and capital markets continue, these markets deteriorate further or there are any ratings downgrades on this ARS we hold, the Company may be required to recognize an additional impairment. In addition, these securities may not provide the necessary liquidity as it could take until the final maturity of the underlying note (June 2034) to realize the investments recorded value. The Company intends to liquidate these securities at par value at the earliest possible opportunity.
9
Inventory
Inventory consists of the following:
March 31, 2008 |
December 31, 2007 |
|||||||
Raw materials |
$ | 1,904,042 | $ | 2,394,846 | ||||
Work in process |
152,701 | 214,996 | ||||||
Finished goods |
9,057,708 | 7,949,723 | ||||||
Reserve for obsolescence |
(577,300 | ) | (595,105 | ) | ||||
$ | 10,537,151 | $ | 9,964,460 | |||||
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
March 31, 2008 |
December 31, 2007 |
|||||||
Prepaid expenses |
$ | 1,115,662 | $ | 1,519,211 | ||||
Deferred cost of revenue |
1,608,124 | 1,176,109 | ||||||
Other assets |
3,148,790 | 1,570,203 | ||||||
5,872,576 | 4,265,523 | |||||||
Less: Long-term other assets |
(744,321 | ) | (844,321 | ) | ||||
Total prepaid expenses and other current assets |
$ | 5,128,255 | $ | 3,421,202 | ||||
Property and Equipment
Property and equipment consist of the following:
March 31, 2008 |
December 31, 2007 |
|||||||
Equipment |
$ | 9,760,849 | $ | 9,637,232 | ||||
Equipment held for lease |
303,412 | 303,412 | ||||||
Leasehold improvements |
1,512,394 | 1,506,576 | ||||||
11,576,655 | 11,447,220 | |||||||
Less: Accumulated depreciation |
(4,969,065 | ) | (4,435,457 | ) | ||||
$ | 6,607,590 | $ | 7,011,763 | |||||
Accrued Liabilities
Accrued liabilities consist of the following:
March 31, 2008 |
December 31, 2007 | |||||
Accrued salaries, bonus, and benefits |
$ | 3,404,819 | $ | 3,531,582 | ||
Accrued research and development |
2,353,056 | 4,456,049 | ||||
Accrued legal and other professional fees |
639,639 | 824,448 | ||||
Other |
2,647,411 | 3,101,339 | ||||
$ | 9,044,925 | $ | 11,913,418 | |||
10
Line of Credit
In February 2008, the Company entered into a Note and Warrant Purchase Agreement with two of its shareholders, pursuant to which those shareholders agreed to loan the Company up to an aggregate of $20 million. These funds can be drawn at the Companys election, would be unsecured and subordinated to any bank debt, and would be due at a maturity date in February 2009. The shareholders also agreed to guarantee advances made to the Company pursuant to the credit agreement with the Companys primary lending bank. The financing commitment from the shareholders is subject to a 90 day extension, solely at the Companys option, providing for an extended maturity date of May 2009. Warrants to purchase 572,246 shares of the Companys common stock at an exercise price of $6.99 were issued to the shareholders in exchange for the financing commitment. The warrants were exercisable immediately upon grant and expire five years from the date of grant. If the Company extends the financing commitment period or the maturity date, it would be required to issue five-year warrants to purchase an additional 143,062 shares of common stock at the same exercise price. The Company recorded the fair value of the warrants in the amount of $1.7 million to be amortized to interest expense over the one year commitment period through February 2009. The unamortized balance as of March 31, 2008 was approximately $1.5 million.
In conjunction with this transaction, the Company and its primary lending bank amended the working capital line of credit by increasing the line to $30 million subject to a borrowing base of qualifying accounts receivable and inventory, with up to $10 million available under the line supported by these guarantees. Under the revised facility the Company is required to maintain a minimum tangible net worth as defined in the agreement of at least $5 million at the end of any calendar quarter during the term of the agreement, with lesser amounts required at non-quarter month ends. As of March 31, 2008, the Company had $5.0 million outstanding under the working capital line of credit and had an unused line of approximately $25.0 million with current borrowing capacity, including amounts already drawn, of approximately $11.1 million based on qualifying receivables and inventory balances. As of March 31, 2008, the Company was in compliance with all covenants of the bank loan agreement.
Stockholders Equity
In March 2007, the Company completed an offering of 1,919,000 shares of its common stock at $10.50 per share. In conjunction with these transactions, the Company received approximately $20.1 million in net proceeds after deducting offering expenses.
Product Warranty Provisions
The Companys standard policy is to warrant all NIOBE and ODYSSEY systems against defects in material or workmanship for one year following installation. The Companys estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.
Accrued warranty consists of the following:
March 31, 2008 |
||||
Warranty accrual at December 31, 2007 |
$ | 234,951 | ||
Warranty expense incurred |
71,217 | |||
Payments made |
(43,243 | ) | ||
Warranty accrual at March 31, 2008 |
$ | 262,925 | ||
Commitments and Contingencies
The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or cash flows of the Company.
11
ITEM 2. | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
The following discussion and analysis should be read in conjunction with our financial statements and notes thereto included in this report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2007. Operating results are not necessarily indicative of results that may occur in future periods.
This report includes various forward-looking statements that are subject to risks and uncertainties, many of which are beyond our control. Our actual results could differ materially from those anticipated in these forward looking statements as a result of various factors, including those set forth in Item 1A Risk Factors and in our Annual Report on Form 10-K for the year ended December 31, 2007. Forward-looking statements discuss matters that are not historical facts and include, but are not limited to, discussions regarding our operating strategy, sales and marketing strategy, regulatory strategy, industry, economic conditions, financial condition, liquidity and capital resources and results of operations. Such statements include, but are not limited to, statements preceded by, followed by or that otherwise include the words believes, expects, anticipates, intends, estimates, projects, can, could, may, will, would, or similar expressions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You should not unduly rely on these forward-looking statements, which speak only as of the date on which they were made. They give our expectations regarding the future, but are not guarantees. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
Overview
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospitals interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The NIOBE system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. In addition to the NIOBE system and its components, Stereotaxis also has developed the ODYSSEY information management system, which consolidates the multiple sources of diagnostic and imaging information found in the interventional lab into a large-screen user interface with single mouse control, which can be connected via a private network line to other interventional labs or to a remote clinical call center. The core components of the NIOBE system and the ODYSSEY system have received regulatory clearance in the U.S., Canada, Europe and various other countries.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We review our estimates and judgments on an on-going basis. We base our estimates and judgments on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates. We believe the following accounting policies are critical to the judgments and estimates we use in preparing our financial statements. For a complete listing of our critical accounting policies, please refer to our Annual Report on Form 10-K for the year ended December 31, 2007.
Revenue Recognition
For arrangements with multiple deliverables, we allocate the total revenue to each deliverable based on the provisions of Staff Accounting Bulletin 104 (SAB 104) Revenue Recognition and Emerging Issues Task Force Issue No. 00-21 (EITF 00-21), Revenue Arrangements with Multiple Deliverables, and recognize revenue for each separate element as the criteria are met. Under EITF 00-21, we are required to continually evaluate whether we have separate units of accounting for deliverables within certain contractual arrangements we have made with customers, specifically as it relates to the sale and installation of our magnetic navigation system. Prior to the quarter ended June 30, 2007, we had met the first criterion for separation of multiple elements under EITF 00-21, which was that the NIOBE system has stand-alone value but had not yet accumulated sufficient evidence to support the determination of fair value on the undelivered installation element. By the second quarter of 2007, we had accumulated sufficient experience to conclude that installation had been and could be performed by several independent vendors such that fair value could be determined. As such, we determined in the second quarter of 2007 that installation met the criteria under SAB 104 and EITF 00-21 for recognition as a separate element or unit of accounting and began to recognize revenue on the delivery and installation of the NIOBE system as two separate elements.
12
Under our revenue recognition policy, revenue for system sales is recognized for the portion of sales price due upon delivery, provided delivery has occurred, title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. The greater of fair market value or the amount of the sales price due upon installation is recognized as revenue when the standard installation process is complete. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since such arrangements do not include an installation element or right of return privileges. If uncertainties exist regarding collectability, we recognize revenue when those uncertainties are resolved. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multi-element arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and an appropriate reserve for returns is established. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus affect on revenue recognized in the period. The Company believes that the estimate is not likely to change significantly in the future.
Results of Operations
Comparison of the Three Months Ended March 31, 2008 and 2007
Revenue. Revenue decreased from $9.2 million for the three months ended March 31, 2007 to $7.0 million for the three months ended March 31, 2008, a decrease of approximately 23%. Revenue from the sale of systems decreased from $7.2 million to $4.4 million, a decrease of approximately 39% because of a decrease in the number of systems delivered from six to four. Revenue from sales of disposable interventional devices, service and accessories increased to $2.7 million for the three months ended March 31, 2008 from $2.0 million for the three months ended March 31, 2007, an increase of approximately 36%. This increase was principally attributable to the increased base of installed systems.
Purchase orders and other commitments for our magnetic navigation system and integrated cath lab display were approximately $66 million at March 31, 2008. We do not include orders for disposables, service or other accessories in the backlog data. Backlog includes amounts withheld at the time of revenue recognition which will included in revenue in the future when the related obligations are completed. There can be no assurance that we will recognize revenue in any particular period or at all because some of our purchase orders and other commitments are subject to contingencies that are outside our control. In addition, these orders and commitments may be revised, modified or cancelled, either by their express terms, as a result of negotiations, or by project changes or delays.
Cost of Revenue. Cost of revenue decreased from $3.3 million for the three months ended March 31, 2007 to $2.4 million for the three months ended March 31, 2008, a decrease of approximately 25%. Cost of revenue for systems sold decreased from $2.5 million for the three months ended March 31, 2007 to $1.9 million for the three months ended March 31, 2008 primarily due to the fewer number of systems sold.
Research and Development Expenses. Research and development expenses decreased from $5.7 million for the three months ended March 31, 2007 to $4.7 million for the three months ended March 31, 2008, a decrease of approximately 17%. The decrease was due principally to a decrease in development related to new product introductions and device development.
General and Administrative Expenses. General and administrative expenses include our regulatory, training, clinical and general management expenses. General and administrative expenses increased to $5.5 million from $4.9 million for the three months ended March 31, 2008 and 2007, respectively, an increase of approximately 11%. The increase was due primarily to increased compensation and related costs related to the expansion of our European operations and training.
Sales and Marketing Expenses. Sales and marketing expenses increased to $7.7 million for the three months ended March 31, 2008 from $6.1 million for the three months ended March 31, 2007, an increase of approximately 26%. The increase related primarily to increased salary, benefits and travel expenses associated with expanded sales headcount and expanded marketing programs.
13
Interest Income. Interest income decreased to $108,000 for the three months ended March 31, 2008 from $382,000 for the three months ended March 31, 2007, a decrease of approximately 72% principally due to lower invested balances.
Interest Expense. Interest expense increased to $403,000 for the three months ended March 31, 2008 from $80,000 for the three months ended March 31, 2007, primarily due to the amortization of warrant expense during 2008 related to the affiliate line of credit and higher average outstanding balances due on our loans during 2008.
Liquidity and Capital Resources
Liquidity refers to the liquid financial assets available to fund our business operations and pay for near-term obligations. These liquid financial assets consist of cash and cash equivalents, as well as investments. In addition to our cash and cash equivalent balances, we maintained $0.5 million of investments in auction rate securities at March 31, 2008 and $6.6 million of investments in commercial paper and auction rate securities at December 31, 2007. At March 31, 2008, we had working capital of approximately $7.2 million, compared to $21.9 million at December 31, 2007.
The following table summarizes our cash flow by operating, investing and financing activities for each of three month periods ended March 31, 2008 and 2007 (in thousands):
Three Months Ended March 31, |
||||||||
2008 | 2007 | |||||||
Cash Flow (used in) operating activities |
$ | (12,441 | ) | $ | (6,288 | ) | ||
Cash Flow provided by investing activities |
$ | 5,987 | $ | 17,136 | ||||
Cash Flow provided by financing activities |
$ | 405 | $ | 20,387 |
Net cash used in operating activities. We used approximately $12.4 million and $6.3 million of cash for operating activities during the three months ended March 31, 2008 and 2007, respectively, primarily as a result of operations during these periods. During the three months ended March 31, 2008, we used approximately $0.9 million to fund operating assets and liabilities. We generated approximately $2.6 million from operating assets and liabilities during the three months ended March 31, 2007.
Net cash provided by investing activities. We generated approximately $6.0 and $17.1 million of cash from investing activities during the three months ended March 31, 2008 and 2007, respectively, principally from the maturity of investments. We used approximately $0.2 million and $1.6 million of cash for the purchase of equipment during the three months ended March 31, 2008 and 2007, respectively.
Net cash provided by financing activities. We generated approximately $20.4 million from financing activities during the three months ended March 31, 2007 primarily from the proceeds of our common stock offering in the first quarter of 2007. For the three months ended March 31, 2008 we received approximately $655,000 from the exercise of stock options offset by amounts repaid under our equipment loan agreements.
Line of Credit
In February 2008, we entered into a Note and Warrant Purchase Agreement with two of our shareholders pursuant to which those shareholders agreed to loan the Company up to an aggregate of $20 million. These funds can be drawn at our election, would be unsecured and subordinated to any bank debt, and would be due at a maturity date in February 2009. The shareholders also agreed to guarantee advances made to the Company pursuant to the credit agreement with our primary lending bank. The financing commitment from the shareholders is subject to a 90 day extension, solely at our option, providing for an extended maturity date of May 2009. We issued warrants to purchase 572,246 shares of our common stock at an exercise price of $6.99 to the shareholders in exchange for the financing commitment. The warrants were exercisable immediately upon grant and expire five years from the date of grant. To the extent such warrants are exercised on a cash basis, we will receive proceeds from the exercise of such warrants; however, we will not receive the proceeds from any sales of the underlying shares by the shareholders. If we elect to extend the commitment period or the maturity date, we will be required to issue an additional 143,062 of the five-year warrants at the same exercise price.
In conjunction with this transaction, we entered into a loan modification agreement with our primary lender to increase the maximum borrowing capacity from $25 million to $30 million subject to a borrowing base of qualifying accounts receivable
14
and inventory, with up to $10 million available under the line supported by these guarantees. Under the revised facility we are required to maintain a minimum tangible net worth as defined in the agreement of at least $5 million at the end of any calendar quarter during the term of the agreement, with lesser amounts required at non-quarter month ends. The revolving line of credit under the loan agreement matures in March 2009 and the interest rate is calculated at a floating per annum rate equal to the greater of the lenders prime rate or 6%. The loan agreement is secured by substantially all of our assets and includes customary affirmative, negative and financial covenants. For example, we are restricted from incurring additional debt, disposing of or pledging our assets, entering into merger or acquisition agreements, making certain investments, allowing fundamental changes to our business, ownership, management or business locations, and from making certain payments in respect of stock or other ownership interests, such as dividends and stock repurchases. We are also required under the loan agreements to maintain our primary operating account and the majority of our cash and investment balances in accounts with the lender. As of March 31, 2008, we had $5.0 million outstanding under our working capital line of credit and had an unused line of approximately $25.0 million with borrowing capacity, including amounts already drawn, of approximately $11.1 million, based on qualifying receivables and inventory balances. As of March 31, 2008, we had aggregate outstanding balances of approximately $1.7 million under our two equipment loan agreements. As of March 31, 2008, we are in compliance with all covenants of this agreement.
Shelf Registration
In August 2006, we filed a universal shelf registration statement for the issuance and sale from time to time to the public of up to $75 million in securities, including debt, preferred stock, common stock and warrants. The shelf registration was declared effective by the SEC in September 2006. In March 2007, we completed an offering of 1,919,000 shares of our common stock at $10.50 per share pursuant to the shelf registration. In conjunction with this transaction, we received approximately $20.1 million in net proceeds after deducting offering expenses. As a result, we have approximately $55 million of remaining availability under the shelf registration statement. In addition, we filed a registration statement relating to the exercise of warrants previously issued in various private financings. To the extent such warrants are exercised on a cash basis, we will receive proceeds from the exercise of such warrants; however, we will not receive the proceeds from any re-sales of the underlying shares.
Cash flow
We expect to have negative cash flow from operations through 2008. Throughout 2008, we expect to continue the development and commercialization of our existing products and our research and development programs and the advancement of new products into clinical development. We expect that our research and development expenditures will decrease in 2008 and our selling, general and administrative expenses will continue to increase in order to support our product commercialization efforts. Until we can generate significant cash flow from our operations, we expect to continue to fund our operations with existing cash resources that were primarily generated from the proceeds of our public offerings, private sales of our equity securities and working capital and equipment financing loans. In the future, we may finance cash needs through the sale of other equity securities, strategic collaboration agreements and debt financings. We cannot accurately predict the timing and amount of our utilization of capital, which will depend on a number of factors outside of our control.
While we believe our existing cash, cash equivalents and investments, and borrowing facilities will be sufficient to fund our operating expenses and capital equipment requirements through the next 12 months, we cannot assure you that we will not require additional financing before that time. We also cannot assure you that such additional financing will be available on a timely basis on terms acceptable to us or at all, or that such financing will not be dilutive to our stockholders. If adequate funds are not available to us, we could be required to delay development or commercialization of new products, to license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize ourselves or to reduce the sales, marketing, customer support or other resources devoted to our products, any of which could have a material adverse effect on our business, financial condition and results of operations.
Off-Balance Sheet Arrangements
We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.
15
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
We have exposure to currency fluctuations. We operate mainly in the U.S., Europe and Asia and we expect to continue to sell our products both within and outside of the U.S. We expect to transact this business primarily in U.S. dollars and in Euros, although we may transact business in other currencies to a lesser extent. Future fluctuations in the value of these currencies may affect the price competitiveness of our products. In addition, because we have a relatively long installation cycle for our systems, we will be subject to risk of currency fluctuations between the time we execute a purchase order and the time we deliver a system and collect payments under the order, which could adversely affect our operating margins. We have not hedged exposures in foreign currencies or entered into any other derivative instruments. As a result, we will be exposed to some exchange risks for foreign currencies. For example, if the Euro currency exchange rate were to fluctuate by 10%, we believe that our revenues could be affected by as much as 2 to 3%.
We have exposure to market risk related to our investments, particularly auction rate securities. At March 31, 2008 we held approximately $500,000 in auction rate securities against which we have taken a $32,000 impairment charge. Auction rate securities are private placement securities with long-term maturities for which the interest rates are reset through a Dutch auction each month. We only invest in auction rate securities with AAA/Aaa ratings at the time of purchase. Although the monthly auctions have historically provided a liquid market for these securities, the recent liquidity issues experienced in the auction rate securities market might make it impossible for us to liquidate our holdings or require that we sell the securities at a substantial loss or take an additional impairment charge.
We also have exposure to interest rate risk related to our investment portfolio and our borrowings. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive from our invested cash without significantly increasing the risk of loss.
Our interest income is sensitive to changes in the general level of U.S. interest rates, particularly since we often invest in short-term debt instruments. We invest our excess cash primarily in U.S. government securities and marketable debt securities of financial institutions and corporations with strong credit ratings. These instruments generally have maturities of two years or less when acquired. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions. Accordingly, we believe that while the instruments we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments.
We do not believe that inflation has had a material adverse impact on our business or operating results during the periods covered by this report.
ITEM 4. | CONTROLS AND PROCEDURES |
Disclosure Controls and Procedures: The Companys management, with the participation of the Companys Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Companys disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), as of the end of the period covered by this report. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, the Companys Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Companys disclosure controls and procedures were effective.
Changes In Internal Control Over Financial Reporting: The Companys management, with the participation of the Companys Chief Executive Officer and Chief Financial Officer, also conducted an evaluation of the Companys internal control over financial reporting to determine whether any changes occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting. Based on that evaluation, there has been no such change during the period covered by this report.
16
PART II OTHER INFORMATION
ITEM 1. | LEGAL PROCEEDINGS |
We are involved from time to time in various lawsuits and claims arising in the ordinary course of business. Although the outcomes of these lawsuits and claims are uncertain, we do not believe any of them will have a material adverse effect on our business, financial condition or results of operations.
ITEM 1A. | RISK FACTORS |
There have been no material changes to our risk factors as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2007 (as filed with the SEC on March 17, 2008).
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
As previously reported on Form 8-K, during the quarter ended March 31, 2008, the Company issued warrants to purchase an aggregate of 572,246 shares of its common stock at an exercise price of $6.99 per share in connection with a loan agreement pursuant to which affiliates two of the Companys current shareholders, Sanderling Venture Partners and Alafi Capital (the Lenders), committed to loan the Company an aggregate of $20 million. The warrants will be exercisable for a period expiring five years from the date of grant. If the loan commitment or the maturity date of any loan drawn under the loan is extended pursuant to the terms of the loan agreement, the Company will be obligated to issue an additional 143,062 five-year common stock warrants at the same exercise price.
The issuance of warrants was made without any public solicitation to a total of four accredited investors who acquired the warrants for investment purposes only. The investors had access to complete information about the Company and were deemed capable of evaluating the merits and risks of this investment. The securities were issued pursuant to the private placement exemption provided by Section 4(2) of the Securities Act of 1933 (Securities Act). These warrants and the shares issuable upon exercise will be deemed to be restricted securities as defined in Rule 144 under the Securities Act and will bear a legend stating the restrictions on resale. Any funds raised from the exercise of the warrants will be utilized by the Company for general corporate purposes.
ITEM 3. | DEFAULTS UPON SENIOR SECURITIES |
None.
ITEM 4. | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS |
None.
ITEM 5. | OTHER INFORMATION |
None.
ITEM 6. | EXHIBITS AND REPORTS ON FORM 8-K |
(a) | Exhibits: See Exhibit Index herein |
17
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
STEREOTAXIS, INC. | ||||||
(Registrant) | ||||||
Date: | May 9, 2008 | By: | /s/ Bevil J. Hogg | |||
Bevil J. Hogg, | ||||||
Chief Executive Officer | ||||||
Date: | May 9, 2008 | By: | /s/ James M. Stolze | |||
James M. Stolze, Vice President and | ||||||
Chief Financial Officer |
18
Number |
Description | |
3.1(1) | Restated Certificate of Incorporation of the Company | |
3.2(1) | Restated Bylaws of the Company | |
10.1 | Employment Agreement dated February 1, 2008 between Kevin Shifrin and Registrant | |
31.1 | Rule 13a-14(a)/15d-14(a) Certification (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, executed by Chief Executive Officer). | |
31.2 | Rule 13a-14(a)/15d-14(a) Certification (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, executed by Chief Financial Officer). | |
32.1 | Section 1350 Certification (pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by Chief Executive Officer). | |
32.2 | Section 1350 Certification (pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by Chief Financial Officer). |
(1) | This exhibit was previously filed as an exhibit to the Registrants Quarterly Report on Form 10-Q for the quarter ended March 31, 2004 (filed November 12, 2004) (File No. 000-50884), and is incorporated herein by reference. |
19
EXHIBIT 10.1
January 31, 2008
Kevin Shifrin
4264 North Morning Dove Circle
Mesa, Arizona 85207
Dear Kevin:
I am pleased to extend you an offer to join Stereotaxis as Senior Vice President, Global Marketing and Strategic Planning. Your position will be located in our St. Louis, MO facility. This letter outlines the terms of your employment offer.
Your annualized base salary will be $270,000 payable semi-monthly. You will be eligible to participate in the Corporate Bonus Plan with a bonus potential of up to 50% of your base salary based upon achieving specific corporate and individual objectives (see attached draft of 2008 Corporate Objectives). You will be eligible for a full year of participation assuming a start date of March 15, 2008 or earlier.
You will also receive a gross lump sum signing bonus of $50,000 (less all required deductions) payable after 60 days of continuous employment with the Company. The payment will be processed in accordance with the Companys regular payroll schedule. This bonus will be subject to recovery should you voluntarily resign within one year of employment.
As per our discussion, this letter confirms that Management has a goal for 2009 to move toward a greater emphasis on cash incentives as a part of total compensation for its senior management team. Your position will be included in any changes that are implemented. Please understand that such changes are subject to Board approval.
Additionally, I will recommend that the Board of Directors grant you 25,000 Performance Based Restricted shares of the Companys stock at its next regular meeting. Performance Based Restricted shares shall vest as specific corporate performance goals are achieved per the attached Performance Share summary which includes the goals. There are no time limitations on vesting. However, if any of the performance criteria are not met on or before June 15, 2010, the portion of shares subject to that criteria will be forfeited. All shares shall be subject to the other terms and conditions set forth in the Companys stock option plan and the Performance Share Agreement (see attached agreement). Such grant is subject to the final approval of the Board of Directors.
I will also recommend that the Board of Directors grant you options to purchase up to 125,000 shares of the Companys stock. These options will vest 25% after the first year and then monthly thereafter at the rate of 2.0833% per month such that all rights are available by the end of 4 years from the date of grant. The options will be treated as Incentive Stock Options to the extent allowed under the IRS Code. All shares shall be subject to the other terms and conditions set forth in the Companys stock option plan and the Incentive Stock Option Agreement (see attached agreement). Such grant is subject to the final approval of the Board of Directors.
Along with this initial grant, you will be eligible for annual equity grants starting in 2009. Any future awards will be based on Company guidelines for your position and your performance. All grants are subject to Board approval.
As you know, this position will ultimately be located in St. Louis, MO and you will be expected to relocate to the St. Louis area in a timely manner. To facilitate your physical relocation, and subject to prior approval, you will be reimbursed for reasonable relocation expenses according to the terms of the attached relocation program. This program includes provisions for the sale of your home, the physical move of your household goods to St. Louis, temporary living for you and your family as well as assistance with the purchase of a home in St. Louis. In addition, any taxable relocation expenses will be grossed up. Any payments made to you or on your behalf with respect to this relocation will be subject to recovery should you voluntarily resign within one year of relocation.
You shall be entitled to the standard benefits (see attached benefit summary) made available by the Company from time to time including medical and dental insurance for you and your family (subject to employee contributions) and paid time off for vacation and sick time (PTO) of fifteen days per year accumulated at a rate of 1.25 days per month.
Stereotaxis is an at-will employer, which means that you or Stereotaxis may terminate your employment at any time, with or without cause and without notice. You will be required to execute the Companys standard At-Will-Employment Agreement and Confidentiality and Non-compete Agreement, which includes provisions relating to arbitration of employment disputes. If you are terminated for other than cause you will receive a guarantee of 6 months severance.
By signing this letter, you agree that you are not a party to any employment agreement, non-compete agreement or confidentiality agreement that might be inconsistent with your agreement with Stereotaxis. You must also furnish us with proof that you are authorized to work in the US.
Kevin, we welcome you to Stereotaxis and are enthusiastic about working with you to build our company. This letter contains all the terms and conditions of the Companys offer of employment to you and any previous discussions, understandings or agreements are superseded by this letter. This offer is contingent upon your completion of the Companys standard employment application and the Companys satisfactory completion of its checks on your background. If the foregoing terms are acceptable, please indicate your agreement by signing this letter in the space provided below at your earliest convenience but not later than five days from the date of this letter.
Sincerely,
Mike Kaminski |
President and COO |
ACCEPTED and AGREED this 1st day of February of 2008.
My starting date will be the 25th day of March 2008.
/s/ Kevin Shifrin |
Kevin Shifrin |
AT-WILL EMPLOYMENT AGREEMENT
It is understood and agreed that the employment by Stereotaxis, Inc., a Delaware corporation (the Company or Stereotaxis), of the employee named below (Employee) shall be subject to the terms and conditions of this At-Will Agreement (Agreement).
1. | Position; Base Salary; Incentive Compensation. |
Employee shall serve as Senior Vice President, Global Marketing and Strategic Planning or in such other capacity or capacities as Stereotaxis may from time to time direct. Employee shall report to Mike Kaminski, President and COO or such other person as the Company may from time to time direct. Employees supervisor shall schedule employees hours of work and Employees position with the Company is Exempt.
Employee shall be paid according to the terms of his offer letter, or as provided in the future by Employer from time to time in writing. Such payments shall be subject to applicable withholdings and deductions.
2. | Vacation and Sick Leave Benefits. |
Company-paid vacation and sick leave will be governed by the Employee Handbook.
3. | Company Benefits. |
While employed by the Company, Employee shall be entitled to receive the benefits of employment as the Company may offer from time to time. Employee agrees that as a condition of Employees employment by the Company that Employee will be bound and subject to the terms and conditions of the Companys Employee Handbook. The Employee Handbook may be revised from time to time at the sole discretion of the Company with or without prior notice.
4. | Attention to Duties; Conflict of Interest. |
While employed by the Company, Employee shall devote Employees full business time, energy and abilities exclusively to the business and interests of Stereotaxis, and shall perform all duties and services in a faithful and diligent manner and to the best of Employees abilities. Employee shall not, without the Companys prior written consent, render to others, services of any kind for compensation, or engage in any other business activity that would materially interfere with the performance of Employees duties under this Agreement. Employee represents that Employee has no other outstanding commitments inconsistent with any of the terms of this Agreement or the services to be rendered to Stereotaxis. While employed by the Company, Employee shall not, directly or indirectly, whether as a partner, employee, creditor, shareholder, or otherwise, promote, participate or engage in any activity or other business competitive with the Companys business. Employee shall not invest in any company or business, which competes in any manner with the Company, except that Employee may invest in companies whose securities are listed on the national securities exchanges, provided such investment amounts to less than one (1) per cent of the outstanding equity of the company.
5. | Proprietary Information and Non-competition. |
Employee agrees to be bound by the terms of the Confidentiality and Noncompete Agreement attached as Exhibit A and incorporated by this reference (Confidentiality and Noncompete Agreement), and by the rules of confidentiality and prohibitions against competition promulgated by Stereotaxis from time to time.
6. | At-Will Employer. |
The Company is an at-will employer. This means that the Company may terminate Employees employment at any time, with or without cause, and that Employee may terminate Employees employment at any time, with our without cause. Stereotaxis makes no promise that Employees employment will continue for a set period of time, nor is there any promise that it will be terminated only under particular circumstances. No raise or bonus, if any, shall alter Employees status as an at-will employee or create any implied contract of employment. Discussion of possible or potential benefits in future years is not an express or implied promise of continued employment. No manager, supervisor or officer of Stereotaxis has the authority to change Employees status as an at-will employee. The at-will nature of the employment relationship with Employee can only be altered by a written agreement signed by each member of the Board of Directors of Stereotaxis. No position within Stereotaxis is considered permanent.
7. | Binding Arbitration. |
Any dispute, claim or controversy with respect to Employees termination of employment with the Company (whether the termination of employment is voluntary or involuntary), and any dispute, claim or controversy with respect to incidents or events leading to such termination or the method or manner of such termination, and any question of arbitrability hereunder, shall be settled exclusively by arbitration.
Employee and Stereotaxis each waive their constitutional rights to have such matters determined by a jury. Instead of a jury trial, Stereotaxis and Employee shall choose an arbitrator. Arbitration is preferred because, among other reasons, it is quicker, less expensive and less formal than litigation in court. The provisions governing arbitration shall be described in detail in Stereotaxiss Employee Handbook.
The arbitrator shall not have the authority to alter, amend, modify, add to or eliminate any condition or provision of this Agreement, including, but not limited to, the at-will nature of the employment relationship. The arbitration shall be held in St. Louis, Missouri. The award of the arbitrator shall be final and binding on the parties. Judgment upon the arbitrators award may be entered in any court, state or federal, having jurisdiction over the parties. If a written request for arbitration is not made within one (1) year of the date of the alleged wrong or violation, all remedies regarding such alleged wrong or violation shall be waived.
Should any court determine that any provision(s) of this Agreement to arbitrate is void or invalid, the parties specifically intend every other provision of this Agreement to arbitrate to remain enforceable and intact. The parties explicitly and definitely prefer arbitration to recourse to the courts, for the reasons described above, and have prescribed arbitration as their sole and exclusive method of dispute resolution.
8. | No Inconsistent Obligations. |
Employee represents that Employee is not aware of any obligations, legal or otherwise, inconsistent with the terms of this Agreement or Employees undertakings under this Agreement.
9. | Miscellaneous. |
Stereotaxis may assign this Agreement and Employees employment to an affiliated entity to which the operations it currently manages are transferred.
No promises or changes in Employees status as an employee of the Company or any of the terms and conditions of this Agreement can be made unless they are made in writing and approved by the Board of Directors of Stereotaxis. This Agreement and the terms and conditions described in it cannot be changed orally or by any conduct of either Employee or Stereotaxis or any course of dealings between Employee, or another person and Stereotaxis.
Unless otherwise agreed upon in writing by the parties, Employee, after termination of any employment, shall not seek nor accept employment with the Company in the future and the Company is entitled to reject without cause any application for employment with the Company made by Employee, and not hire Employee. Employee agrees that Employee shall have no cause of action against the Company arising out of any such rejection.
This agreement and performance under it, and any suits or special proceedings brought under it, shall be construed in accordance with the laws of the United States of America and the State of Missouri and any arbitration, mediation or other proceeding arising hereunder shall be filed and adjudicated in St. Louis, Missouri.
If any term or condition, or any part of a term or condition, of this Agreement shall prove to be invalid, void or illegal, it shall in no way affect, impair or invalidate any of the other terms or conditions of this Agreement, which shall remain in full force and effect.
The failure of either party to enforce any provision of this Agreement shall not be construed as a waiver of or acquiescence in or to such provision.
The Parties to this Agreement represent and acknowledge that in executing this Agreement they do not rely and have not relied upon any representation or statement made by the other party or the other partys agents, attorneys or representatives regarding the subject matter, basis, or effect of this Agreement or otherwise, other than those specifically stated in this written Agreement. This Agreement shall be interpreted in accordance with the plain meaning of its terms and not strictly for or against any party. This Agreement shall be construed as if each party was its author and each party hereby adopts the language of this Agreement as if it were his, her or its own. The captions to this Agreement and its sections, subsections, tables and exhibits are inserted only for convenience and shall not be construed as part of this Agreement or as a limitation on or broadening of the scope of this Agreement or any section, subsection, table or exhibit.
Employee and Stereotaxis have executed this Agreement and agree to enter into and be bound by the provisions hereof as of 25 March 2008.
THIS CONTRACT CONTAINS A BINDING ARBITRATION PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.
Stereotaxis, Inc. | ||
By: | /s/ Sarah Kamp | |
Name: | Sarah Kamp | |
Title: | Manager, Human Resources |
Employee | ||
Signature: | /s/ Kevin Shifrin | |
Name: | Kevin Shifrin |
EXHIBIT A
CONFIDENTIALITY AND NONCOMPETE AGREEMENT
This Confidentiality and Noncompete Agreement (Agreement) is made and entered into this 25th day of March, 2008, by and between Stereotaxis, Inc., a Delaware corporation (Company), and Kevin Shifrin, (Employee).
WHEREAS, Company is engaged in, among other things, the business of research, development, marketing and selling of medical devices and equipment. The Company is headquartered and its principal place of business is located in St. Louis, Missouri;
WHEREAS, Company has expended a great deal of time, money and effort to develop and maintain its proprietary Confidential and Trade Secret Information (as defined herein) which provides it with a significant competitive advantage;
WHEREAS, the success of Company depends to a substantial extent upon the protection of its Confidential and Trade Secret Information and customer goodwill by all of its employees;
WHEREAS, Employee desires to be employed, or to continue to be employed, by Company to provide managerial, administrative, technical and/or sales services for Company; to be eligible for opportunities for advancement within Company and/or compensation increases which otherwise would not be available to Employee; and to be given access to Confidential and Trade Secret Information of Company which is necessary for Employee to perform his or her job, but which Company would not make available to Employee but for Employees signing and agreeing to abide by the terms of this Agreement as a condition of Employees employment and continued employment with Company. Employee recognizes and acknowledges that Employees position with Company has provided and/or will continue to provide Employee with access to Companys Confidential and Trade Secret Information;
WHEREAS, Company compensates its employees to, among other things, develop and preserve goodwill with its customers on Companys behalf and business information for Companys ownership and use;
WHEREAS, If Employee were to leave Company, Company, in all fairness, would need certain protections in order to prevent competitors of Company from gaining an unfair competitive advantage over Company and/or diverting goodwill from Company, and to prevent misuse or misappropriation by Employee of the Confidential and Trade Secret Information;
WHEREAS, Company desires to obtain the benefit of the services of Employee and Employee is willing to render such services on the terms and conditions hereinafter set forth;
NOW, THEREFORE, in consideration of the compensation and other benefits of Employees employment by Company and the recitals, mutual covenants and agreements hereinafter set forth, Employee and Company agrees as follows:
1. | Employment Services. |
1.1 | Employee agrees that throughout Employees employment with Company, Employee will (i) faithfully render such services as may be delegated to Employee by Company, (ii) devote Employees entire business time, good faith, best efforts, ability, skill and attention to Companys business, and (iii) follow and act in accordance with all of Companys rules, policies and procedures of Company, including, but not limited to, working hours, sales and promotion policies and specific Company rules. |
1.2 | Company means Stereotaxis, Inc. or one of its subsidiaries; whichever is Employees employer. The Subsidiary means any corporation, joint venture or other business organization in which Stereotaxis, Inc. now or hereafter, directly or indirectly, owns or controls more than fifty percent (50%) interest. |
2. | Confidential and Trade Secret Information. |
2.1 | Employee agrees to keep secret and confidential, and not to use or disclose to any third parties, except as directly required for Employee to perform Employees employment responsibilities for Company, any of Companys proprietary Confidential and Trade Secret Information. |
2.2 | Confidential and Trade Secret Information includes any information pertaining to Companys business which is not generally known in the medical devices and medical equipment industry, such as, but not limited to, trade secrets, know-how, processes, designs, products, documentation, quality control and assurance inspection and test data, production schedules, research and development plans and activities, equipment modifications, product formulae and production and recycling records, standard operating procedure and validation records, drawings, apparatus, tools, techniques, software and computer programs and derivative works, inventions (whether patentable or not), improvements, copyrightable material, business and marketing plans, projections, sales data and reports, confidential evaluations, the confidential use, nonuse and compilation by the Company of technical or business information in the public domain, margins, customers, customer requirements, costs, profitability, sales and marketing strategies, pricing policies, operational methods, strategic plans, training materials, internal financial information, operating and financial data and projections, distribution or sales methods, prices charged by or to Company, inventory lists, sources of supplies, supply lists, lists of current or past employees, mailing lists and information concerning relationships between Company and its employees or customers. |
2.3 | During Employees employment, Employee will not copy, reproduce or otherwise duplicate, record, abstract, summarize or otherwise use, any papers, records, reports, studies, computer printouts, equipment, tools or other property owned by the Company, except as expressly permitted or required for the proper performance of his or her duties on behalf of the Company. |
3. | Post-Termination Restrictions. |
Employee recognizes that (i) Company has spent substantial money, time and effort over the years in and in developing its Confidential and Trade Secret Information; (ii) Company pays its employees to, among other things, develop and preserve business information, customer goodwill, customer loyalty and customer contacts for and on behalf of Company; and (iii) Company is hereby agreeing to employ and pay Employee based upon Employees assurances and promises contained herein not to put himself or herself in a position following Employees employment with Company in which the confidentiality of Companys information might somehow be compromised. Accordingly, Employee agrees that during Employees employment with Company, and for a period of two years thereafter, regardless of how Employees termination occurs and regardless of whether it is with or without cause, Employee will not, directly or indirectly (whether as owner, partner, consultant, employee or otherwise):
3.1 | engage in, assist or have an interest in, enter the employment of, or act as an agent, advisor or consultant for, any person or entity which is engaged, or will be engaged, in the development, manufacture, supplying or sale of a product, process, apparatus, service or development which is competitive with a product, process, apparatus, service or development on which Employee worked or with respect to which Employee has or had access to Confidential or Trade Secret Information |
while at Company (Competitive Work), and which Employee seeks to serve in any market which was being served by Employee at the time of Employees termination or was served at any time during Employees last six (6) months of employment by Company. |
3.2 | solicit, call on or in any manner cause or attempt to cause, or provide any Competitive Work to any customer or active prospective customer of the Company with whom Employee dealt, or on whose account he or she worked for which Employee was responsible, or with respect to which Employee was provided or had access to Confidential and Trade Secret Information to divert, terminate, limit, modify or fail to enter into any existing or potential relationship with Company; and |
3.3 | induce or attempt to induce any Employee, consultant or advisor of Company to accept employment or an affiliation involving Competitive Work. |
4. | Acknowledgment Regarding Restrictions. |
Employee recognizes and agrees that the restraints contained in Section 3 are reasonable and enforceable in view of Companys legitimate interests in protecting its Confidential and Trade Secret Information and customer goodwill. Employee understands that the post-employment restrictions contained herein will preclude, for a time, Employees employment with competitors of Company in the medical device and medical equipment industry. Employee understands that the restrictions of Section 3 are not limited geographically in view of Companys nationwide operations and the Confidential and Trade Secret Information and customers to which Employee had access.
5. | Inventions. |
5.1 | Any and all ideas, inventions, discoveries, patents, patent applications, continuation-in-part patent applications, divisional patent applications, technology, copyrights, derivative works, trademarks, service marks, improvements, trade secrets and the like, which are developed, conceived, created, discovered, learned, produced and/or otherwise generated by Employee, whether individually or otherwise, during the time that Employee is employed by Company, whether or not during working hours, that relate to (i) current and anticipated businesses and/or activities of Company, (ii) Companys current and anticipated research or development, or (iii) any work performed by Employee for Company, shall be the sole and exclusive property of Company, and Company shall own any and all right, title and interest to such. Employee assigns and agrees to assign to Company any and all right, title and interest in and to any such ideas, inventions, discoveries, patents, patent applications, continuation-in-part patent applications, divisional patent applications, technology, copyrights, derivative works, trademarks, service marks, improvements, trade secrets and the like, whenever requested to do so by Company, at Companys expense, and Employee agrees to execute any and all applications, assignments or other instruments which Company deems desirable or necessary to protect such interests. |
5.2 | Paragraph 5.1 shall not apply to any invention for which no equipment, supplies, facilities or Confidential and Trade Secret Information of Company was used and which was developed entirely on Employees own time, unless (i) the invention relates to Companys business or to Companys actual or demonstrably-anticipated research or development, or (ii) the invention results from any work performed by Employee for Company. |
6. | Company Property. |
Employee acknowledges that any and all notes, records, sketches, computer diskettes, training materials and other documents relating to the Company obtained by or provided to Employee, or otherwise made, produced or compiled during the course of Employees employment with Company regardless of the type of medium in which they are preserved, are the sole and exclusive property of Company and shall be surrendered to Company upon Employees termination of employment and on demand at any time by Company.
7. | Non-Waiver of Rights. |
Companys failure to enforce at any time any of the provisions of this Agreement or to require at any time performance by Employee of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this Agreement, or any part hereof, or the right of Company thereafter to enforce each and every provision in accordance with the terms of this Agreement.
8. | Companys Right to Injunctive Relief. |
In the event of a breach or threatened breach of any of Employees duties and obligations under the terms and provisions of Sections 2, 3, 5, or 6 hereof, Company shall be entitled, in addition to any other legal or equitable remedies it may have in connection therewith (including any right to damages that may suffer), to temporary, preliminary and permanent injunctive relief restraining such breach or threatened breach. Employee hereby expressly acknowledges that the harm which might result to Companys business as a result of any noncompliance by Employee with any of the provisions of Sections 2, 3 or 5 would be largely irreparable. Employee specifically agrees that if there is a question as to the enforceability of any of the provisions of Sections 2, 3 or 5 hereof, Employee will not engage in any conduct inconsistent with or contrary to such Sections until after the question has been resolved by a final judgement of a court of competent jurisdiction.
9. | Invalidity of Provisions. |
If any provision of this Agreement is adjudicated to be invalid or unenforceable under applicable law in any jurisdiction, the validity or enforceability of the remaining provisions thereof shall be unaffected as to such jurisdiction and such adjudication shall not affect the validity or enforceability of such provisions in any other jurisdiction. To the extent that any provision of this Agreement is adjudicated to be invalid or unenforceable because it is overbroad, that provision shall not be void, but rather shall be limited only to the extent required by applicable law and enforced as to limited. The parties expressly acknowledge and agree that this Section is reasonable in view of the parties respective interests.
10. | Employee Representations. |
Employee represents that the execution and delivery of the Agreement and Employees employment with Company do not violate any previous employment agreement or other contractual obligation of Employee.
11. | Companys Right to Recover Costs and Fees. |
Employee agrees that if Employee breaches or threatens to breach this Agreement, Employee shall be liable for any attorneys fees and costs incurred by the Company in enforcing its rights under this Agreement in the event that a court determines that Employee has breached this Agreement or if the Company obtains injunctive relief against the Employee and is successful on the merits of its claim against employee.
12. | Employment at Will. |
Employee acknowledges that employee is, and at all times will be, an employee-at-will of Company and nothing contained herein shall be construed to alter or affect such employee-at-will status.
13. | Exit Interview. |
To ensure a clear understanding of this Agreement, Employee agrees, at the time of termination of Employees employment, to engage in an exit interview with Company at a time and place designated by Company and at Companys expense. Employee understands and agrees that during said exit interview, Employee may be required to confirm that Employee will comply with Employees obligations under Sections 2, 3 and 5 of this Agreement. Company may elect, at its option, to conduct the exit interview by telephone.
14. | Amendments. |
No modification, amendment or waiver of any of the provisions of this Agreement shall be effective unless in writing specifically referring hereto, and signed by the parties hereto. This Agreement supersedes all prior agreements and understandings between Employee and Company to the extent that any such agreements or understandings conflict with the terms of this Agreement.
15. | Assignments. |
This Agreement shall be freely assignable by Company to, and shall inure to the benefit of, and be binding upon, Company, its successors and assigns and/or any other entity which shall succeed to the business presently being conducted by Company. Being a contract for personal services, neither this Agreement nor any rights hereunder shall be assigned by Employee.
16. | Choice of Forum and Governing Law. |
In light of Companys substantial contacts with the State of Missouri, the parties interests in ensuring that disputes regarding the interpretation, validity and enforceability of this Agreement are resolved on a uniform basis, and Companys execution of, and the making of this Agreement in Missouri, the parties agree that: (i) any litigation involving any noncompliance with or breach of the Agreement, or regarding the interpretation, validity and/or enforceability of the Agreement, shall be filed and conducted exclusively in the state or federal courts in St. Louis County, Missouri; and (ii) the Agreement shall be interpreted in accordance with and governed by the laws of the State of Missouri, with regard for any conflict of law principles.
17. | Headings. |
Section headings are provided in this Agreement for convenience only and shall not be deemed to substantively alter the content of such sections.
PLEASE NOTE: BY SIGNING THIS AGREEMENT, EMPLOYEE IS HEREBY CERTIFYING THAT EMPLOYEE (A) HAS RECEIVED A COPY OF THIS AGREEMENT FOR REVIEW AND STUDY BEFORE EXECUTING IT; (B) HAS READ THIS AGREEMENT CAREFULLY BEFORE SIGNING IT; (C) HAS HAD SUFFICIENT OPPORTUNITY BEFORE SIGNING THE AGREEMENT TO ASK ANY QUESTIONS EMPLOYEE HAS ABOUT THE AGREEMENT AND HAS RECEIVED SATISFACTORY ANSWERS TO ALL SUCH QUESTIONS; AND (D) UNDERSTANDS EMPLOYEES RIGHTS AND OBLIGATIONS UNDER THE AGREEMENT.
IN WITNESS WHEREOF, the parties hereof have caused this Agreement to be executed as of the day and year first above written.
Employee | Stereotaxis, Inc. | |||
/s/ Kevin Shifrin |
/s/ Sarah Kamp | |||
Kevin Shifrin | Sarah Kamp, Human Resources |
Exhibit 31.1
Certification of Principal Executive Officer
I, Bevil J. Hogg, certify that:
1. | I have reviewed this quarterly report on Form 10-Q of Stereotaxis, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a 15(f and 15d 15(f)) for the registrant and have: |
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.
Date: | May 9, 2008 | /s/ BEVIL J. HOGG | ||
Bevil J. Hogg | ||||
Chief Executive Officer | ||||
Stereotaxis, Inc. | ||||
(Principal Executive Officer) |
Exhibit 31.2
Certification of Principal Financial Officer
I, James M. Stolze, certify that:
1. | I have reviewed this quarterly report on Form 10-Q of Stereotaxis, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a 15(f and 15d 15(f)) for the registrant and have: |
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting.; and
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.
Date: | May 9, 2008 | /s/ JAMES M. STOLZE | ||
James M. Stolze | ||||
Vice President and Chief Financial Officer | ||||
Stereotaxis, Inc. | ||||
(Principal Financial Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Stereotaxis, Inc. (the Company) on Form 10-Q for the period ended March 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Bevil J. Hogg, Chief Executive Officer of the Company, certify, pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: | May 9, 2008 | /s/ BEVIL J. HOGG | ||
Bevil J. Hogg | ||||
Chief Executive Officer | ||||
Stereotaxis, Inc. |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Stereotaxis, Inc. (the Company) on Form 10-Q for the period ended March 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James M. Stolze, Vice President and Chief Financial Officer of the Company, certify, pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: | May 9, 2008 | /s/ JAMES M. STOLZE | ||
James M. Stolze | ||||
Vice President and Chief Financial Officer | ||||
Stereotaxis, Inc. |